Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396860 | 0.91 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL20100735 | 0.82 | SMN1; SMN2 (0.34) | ALDH1A1L3MBTL1MEN1KMT2AMAPK1 | |
| SCHEMBL13396728 | 0.81 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL13396678 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1CA2CA1FPR2 | |
| SCHEMBL20100734 | 0.76 | HPGD (0.40) | CYP2C19EPHX2 | |
| SCHEMBL10104155 | 0.76 | AKR1B1 (0.36) | ALDH1A1MEN1KMT2APTPN1 | |
| SCHEMBL12754382 | 0.76 | AKR1B1 (0.36) | ALDH1A1MEN1KMT2APTPN1 | |
| SCHEMBL10119574 | 0.76 | AKR1B1 (0.36) | ALDH1A1MEN1KMT2APTPN1 | |
| SCHEMBL20100741 | 0.75 | HPGD (0.44) | ALDH1A1MEN1KMT2ACYP2C19 | |
| SCHEMBL9828854 | 0.75 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1FPR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | ALDH1A1 360/4885L3MBTL1 4339/4885CA2 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.